Histopathological evaluation of fatty and alcoholic liver diseases

Journal of Digestive Diseases

Volumn 12, Issue 1, 2011, Pages 17-24

  Yerian, Lisa ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Fatty liver; Steatohepatitis; Steatosis

Indexed keywords

ALCOHOL LIVER DISEASE; CLINICAL EVALUATION; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FATTY LIVER; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INFLAMMATORY INFILTRATE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; REVIEW;

DIAGNOSIS, DIFFERENTIAL; FATTY LIVER, ALCOHOLIC; HUMANS; LIVER; PATHOLOGY, CLINICAL;

EID: 79251555655     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2010.00472.x     Document Type: Review

References (29)

1. Hautekeete ML, Geerts A. The hepatic stellate (Ito) cell: its role in human liver disease. Virchows Arch 1997; 430: 195-207.
2. Szczepaniak LS, Nurenberg P, Leonard D etal. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-468.
3. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-93.
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-41.
5. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745-9.
6. Center for Disease Control and Prevention. U.S. Obesity Trends. Trends by State 1985-2009. Cited: 7 December 2010. Available from URL.
7. Cornier MA, Dabelea D, Hernandez TL etal. The metabolic syndrome. Endocr Rev 2008; 29: 777-822.
8. Center for Disease Control and Prevention. Trends in Childhood Obesity. Cited: 7 December 2010. Available from URL.
9. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
10. Brunt EM, Kleiner DE, Wilson LA etal. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 809-20.
11. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Gastroenterology 1980; 55: 434-8.
12. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 2003; 98: 2042-7.
13. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.
14. Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-71.
15. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol 2007; 128: 837-47.
16. Schwimmer JB, Behling C, Newbury R etal. Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology 2005; 42: 641-9.
17. Carter-Kent CA, Yerian LM, Brunt EM etal. Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study. Hepatology 2009; 50: 1113-20.
18. Schwimmer JB. Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. Semin Liver Dis 2007; 27: 312-8.
19. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histologic scoring system for nonalcoholic fatty liver disease. Hepatoloogy 2005; 41: 1313-21.
20. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008; 821-8.
21. Nayak NC, Vasdev N, Saigal S, Soin AS. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol 2010; 41: 425-30.
22. Ayata G, Gordon FD, Lewis WD etal. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol 2002; 33: 1098-104.
23. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
24. Tiniakos DG. Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients. Gastroenterol Clin Biol 2009; 33: 930-9.
25. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009; 360: 2758-69.
26. Machado MV, Cortez-Pinto H. Insulin resistance and steatosis in chronic hepatitis C. Ann Hepatol 2009; 8 (Suppl 1): S67-75.
27. Lok AS, Everhart JE, Chung RT etal. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology 2009; 49: 1828-37.
28. Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci 2009; 54: 2699-2705.
29. Bedossa P, Moucari R, Chelbi E etal. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007; 46: 380-7.